Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025
SHANGHAI, April 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics,...
ONO PHARMA USA Announces 2025 Golden Ticket CompetitionNow Accepting Applications from Innovative Startups
Ono Partnering with LabCentral and MBC BioLabs for Fifth Consecutive Year CAMBRIDGE, Mass., April 27, 2025 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San...
MDJM LTD Announces Receipt of Nasdaq Delisting Determination and Plan to Request a Hearing before the Nasdaq Hearings Panel
LETHAM, Scotland, April 26, 2025 /PRNewswire/ -- MDJM LTD (Nasdaq: UOKA) (the "Company" or "MDJM"), an integrated global culture-driven asset management company, today announced that the Company received a staff determination letter (the "Letter"),...
ReTo Eco-Solutions, Inc. Announces Acquisition of Majority Interest in MeinMalzeBier Holdings Limited
BEIJING, April 25, 2025 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (Nasdaq: RETO) ("ReTo" or the "Company"), a manufacturer of ecological environment protection equipment and intelligent equipment in China, today announced that on April 25, 2025, it...
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND)...
Announcement of Paper Publication: EditForce Demonstrates Efficacy of Treatment for Myotonic Dystrophy Type 1 Using PPR Platform Technology
FUKUOKA, Japan, April 25, 2025 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, Japan) is pleased to announce that a research paper on the results of a joint study with the research group led by Professor Masayuki Nakamori of the Department...
LianLian Global Announces Strategic Partnerships with Veem and 12Victory at Money20/20 Asia
Cross-border payments platform outlines global expansion strategy and unveils new real-time remittance and B2B solutions BANGKOK, April 25, 2025 /PRNewswire/ -- LianLian Global, a flagship brand of Hong Kong-listed digital payments provider Lianlian...
Yutong Bus Announces Major Milestone for "Net Zero Forest" Initiative on Earth Day 2025: One Tree Planted per Bus in Operation
Pioneering Sustainability Program Integrates Green Mobility with Ecological Restoration, Reinforcing Leadership in Low-Carbon Innovation ZHENGZHOU, China, April 25, 2025 /PRNewswire/ -- Yutong Bus ("Yutong", SHA: 600066), a commercial vehicle...
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
HONG KONG, April 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in...
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA) in treating NIAU Clinically meaningful...